Evidence map›Paper›PMID 33569343›Full record

ArticleFrontiers in oncology2020

Effectiveness of Cyanoacrylate in Reducing Seroma Formation in Breast Cancer Patients Post-Axillary Dissection: A Randomized Controlled Trial.

Mahmoud Al-Masri, Fade Alawneh, Faiez Daoud, Ali Ebous, Basem Hamdan, Hani Al-Najjar, Rama Al-Masri, Marwan Abufara

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02141373 (Effectivenes of Cyanoacrylate), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02141373 naunknown statusnot on this map

Effectivenes of Cyanoacrylate (Glubran 2®) in Reducing Seroma Formation in Breast Cancer Patients Post-Axillary Dissection

TypeinterventionalSponsorKing Hussein Cancer CenterRan2013Enrolled136ConditionsBreast CancerArmsGlubran 2
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Seroma incidence and risk factors in women undergoing mastectomies as surgical breast cancer treatment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mahmoud Al-MasriDepartment of Surgery, King Hussein Cancer Center, Amman, Jordan.
Fade AlawnehDepartment of Surgery, King Hussein Cancer Center, Amman, Jordan.
Faiez DaoudDepartment of Surgery, King Hussein Cancer Center, Amman, Jordan.
Ali EbousDepartment of Surgery, King Hussein Cancer Center, Amman, Jordan.
Basem HamdanDepartment of Surgery, King Hussein Cancer Center, Amman, Jordan.
Hani Al-NajjarDepartment of Surgery, King Hussein Cancer Center, Amman, Jordan.
Rama Al-MasriSchool of Medicine, University of Jordan, Amman, Jordan.
Marwan AbufaraDepartment of Surgery, King Hussein Cancer Center, Amman, Jordan.
King Hussein Cancer Center · JOUniversity of Jordan · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background/purposeSeroma is a common complication after axillary dissection in women with node-positive breast cancer. We aim to determine the effect of Cyanoacrylate on reducing seroma formation in patients undergoing axillary dissection. This a randomized clinical trial.

methodsThis is a single-center, randomized, single-blinded, and two-arm parallel study. Women with node-positive breast cancer eligible for axillary dissection were enrolled. Patients with a Body Mass Index (BMI) greater than 35 kg/m

results111 patients were randomized (Cyanoacrylate 57; control 54). 105 patients were analyzed. Sixty-nine patients underwent breast conserving surgery, and 36 underwent modified radical mastectomy. There was no difference in the total seroma volume between the Cyanoacrylate vs. control arms (1,304 (60-4,950) vs. 1,446 (100-5,223) ml,

conclusionCyanoacrylate did not reduce seroma formation and its use was not cost effective. CLINICAL

trial registrationclinicaltrials.gov, identifier NCT02141373.

Indexed as

axillabreast cancerbreast surgerycyanoacrylateseroma

Identifiers

PMID33569343
PMCPMC7868378
OpenAlexW3121872906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.